Sugar moieties in natural products are frequently modified by
O-methylation. In the biosynthesis of the macrolide antibiotic
mycinamicin, methylation of a 6′-deoxyallose substituent occurs in a stepwise
manner first at the 2′- and then the 3′-hydroxyl groups to produce the
mycinose moiety in the final product. The timing and placement of the
O-methylations impact final stage C-H functionalization reactions
mediated by the P450 monooxygenase MycG. The structural basis of pathway ordering and
substrate specificity is unknown. A series of crystal structures of MycF, the
3′-O-methyltransferase, including the free enzyme and complexes
with S-adenosyl homocysteine (SAH), substrate, product, and unnatural
substrates, show that SAM binding induces substantial ordering that creates the binding
site for the natural substrate, and a bound metal ion positions the substrate for
catalysis. A single amino acid substitution relaxed the 2′-methoxy specificity but
retained regiospecificity. The engineered variant produced a new mycinamicin analog,
demonstrating the utility of structural information to facilitate bioengineering
approaches for the chemoenzymatic synthesis of complex small molecules containing modified
sugars. Using the MycF substrate complex and the modeled substrate complex of a
4′-specific homolog, active site residues were identified that correlate with the
3′- or 4′- specificity of MycF family members and define the protein and
substrate features that direct the regiochemistry of methyltransfer. This classification
scheme will be useful in the annotation of new secondary metabolite pathways that utilize
this family of enzymes.